Cymabay Therapeutics Gross Profit

The latest gross profit for CBAY is $30M as of December 2023. That compares with $-540K in the prior-year period — up 5717.7% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Cymabay Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CBAY's gross profit moved from $-540K to $30M — a 5717.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cymabay Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, CBAY currently prints $30M for gross profit, while the sector average sits near $67B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Cymabay Therapeutics's growth, margins, and balance sheet.

A gross profit figure of $30M for CBAY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting CBAY's gross profit ($30M), review year-over-year change from $-540K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.